XKEM aktuel empfohlen unter:

das sind natürlich gerundet 0,03 US Dollar  

 

 

 

September 4th, 2006
Commercial distribution of local sickle cell drug begins


Xechem Pharmaceuticals Nigeria has been given the mandate to market a drug produced locally to combat sickle cell.
The drug, Nisprisan, was found and developed by the National Institute for Pharmaceutical Research and Development.

Director-General of NAFDAC, Dora Akunyili made this known in a paper she delivered on ``Sickle Cell Disease: Challenges and Control.'' The paper was presented in Awka on Thursday at this year's African Sickle Cell Day organized by the Orient Sickle Cell Foundation.

``The drug has since been registered by NAFDAC and is now being distributed commercially by Xechem Pharmaceuticals Nigeria as `Nicosan','' she said.

Akunyili said the development was a step in the right direction and urged people suffering from sickle cell not lose hope because theirs was not a hopeless situation.

``I want to remind sickle cell patients that they should disbelieve the impression that they are unlikely to reach adulthood, much less middle or old age.

I encourage you to put in the best of your effort in whatever you do as current researches have proved otherwise. You can live to adulthood with the right medication, '' she said. The director-general said sickle cell was a big challenge to Africans, especially Nigerians who, she said, had the largest population of sickle cell sufferers.

``Sickle cell is not going to go away unless concerted efforts are made by all stakeholders to combat it.

A national programme implemented for this purpose will certainly generate organizational skills and insight, which will be valuable in the execution of other health care initiatives,'' she added. She suggested that the management of sickle cell anaemia should be based at the primary health care level, with emphasis on programmes that could reach more people using affordable technology.

Akunyili assured Nigerians that the agency would always ensure the quality, safety and efficacy of drugs used in the management of sickle cell.
 

 

http://www.businessdayonline.com/?c=44&a=8346
 

noch nicht abgeschlossen.  

auf längere Sicht (12-24 Mo) ist die Aussicht viel besser...


The faster a company grows, the higher its stock's P/E can be. Contrary to popular belief, PEG (P/E over Growth Rate) need not always be 1.00 or less. But all else being equal, lower is
better (and 3.00 is usually too high). Try to favor company PEGs that are lower than industry and market PEGs. In all cases, watch for very high growth estimates. If overly optimistic
projections get cut, PEG would wind up being higher. FY = Fiscal Year.
Price/EPS (Est.) for Current FY Price/EPS (Est.) for Next FY Long Term Growth Estimate Next FY P/E over LT Growth
Xechem International, Inc NA NA NA NA
Biotechnology & Drugs 32.59 24.42 22.12 1.25
S&P 500 17.66 15.31 12.00 1.44
Comparative Valuation Ratios

Valuation below industry or S&P 500 averages can be attractive - unless the company is materially worse in terms of quality
growth prospects. Year-by-year trends in comparative valuations can give clues about company merit. Be especially on guard
if comparative ratios are deteriorating over time. On the other hand, relatively low valuations that are moving toward the
averages might indicate that the market is tuning in to heretofore under-appreciated company merit.
FY = Fiscal Year, TTM = Trailing Twelve Months, * = Most Recent Quarter.
Xechem International, Inc
Price/
Earnings
Price/
Sales
Price/
Book
Price/
Cash Flow
Price/
Tang. Book
Price/Free
Cash Flow
Trailing 12 Months NA 4,884.17 * NA NA * NA NA
FY Ending 12/31/05 NM NM (0.91) (0.38) (0.91) (0.81)
FY Ending 12/31/04 NM 23.58 (7.35) (0.23) (7.35) (0.83)
FY Ending 12/31/03 NM 4.96 (6.04) (0.43) (6.04) (0.80)
FY Ending 12/31/02 NM 2.24 (0.78) (0.18) (0.78) (0.47)
Bar Chart Key
2002RTTM
Biotechnology & Drugs
Price/
Earnings
Price/
Sales
Price/
Book
Price/
Cash Flow
Price/
Tang. Book
Price/Free
Cash Flow
Trailing 12 Months 35.95 9.14 * 6.57 28.14 * 15.92 38.83
FY Ending 2005 48.30 11.87 6.87 28.05 10.38 39.10
FY Ending 2004 46.50 11.69 5.29 24.44 10.13 36.13
FY Ending 2003 43.50 12.04 5.63 24.06 9.55 27.30
FY Ending 2002 40.55 9.68 4.33 0.44 8.45 34.84
Bar Chart Key
2002RTTM
S&P 500
Price/
Earnings
Price/
Sales
Price/
Book
Price/
Cash Flow
Price/
Tang. Book
Price/Free
Cash Flow
Trailing 12 Months 19.61 2.74 * 3.67 13.86 * 7.20 30.56
FY Ending 2005 22.68 3.02 4.28 15.50 6.14 22.91
FY Ending 2004 24.57 3.20 4.10 15.72 5.80 24.19
FY Ending 2003 29.58 3.32 4.17 18.58 5.76 27.71
FY Ending 2002 27.62 2.95 4.35 16.42 5.22 26.21
Bar Chart Key
2002RTTM
Dividends
Dividend is the most classic basis for
stockvaluation, and high dividend yields are
usuallydeemed preferable. Today, with many
companiesreinvesting profits back into the
business, moderateor low yields can be accepted if
dividends growrapidly. The main risk is that poor
performance willcause the dividend to be cut or
omitted. A very highpayout ratio is one warning
signal. Another is ayield that is very high relative to
industry peers.
TTM = Trailing Twelve Months.
XKEM Industry
Current Dividend Yield NA 0.6%
5 Yr. Avg. Dividend Yield 0.0% 0.1%
5 Yr. Dividend Growth Rate NA (32.9)%
TTM Payout Ratio NA 0.7%
5 Yr. Average Payout Ratio NA 0.3%
Liquid Assets
Get a general sense of the extent to which the
stockprice is offset by the presence of assets that
can beconverted to cash immediately or in the near
future. Often, these ratios will not be meaningful.
Most companies are valued as ongoing businesses,
rather than liquidation/buyout prospects. If you're
lookingat an especially troubled company, be aware
that seemingly liquid-asset windfalls can be
dissipatedby continuing operating losses and/or
shutdown costs.
Price to ... XKEM Industry
General Working Capital (5.2) 14.9
(current assets minus current liabilities)
Net Working Capital (4.0) 7.5
(current assets minus all liabilities)
Cash (& cash equivalents) NM 18.8
Cash minus total debt (5.4) (2.0)
Cash minus all liabilities (3.8) (8.9)
Xechem International, Inc (OTC:XKEM) -- Biotechnology & Drugs/Healthcare Reuters Company Research
Stock Price Rationale
Determine if the stock price is justified by: growth-based value, comparative value, liquid assets, or dividends. The better the company, (in terms of growth or quality), the higher the
valuation measures can be. And if valuation ratios are extremely low, double-check to see if the company appears excessively weak. In any case, you don't have to say yes to any
valuation measure - many buy shares based on other factors (e.g., growth). But if you do that, at least understand what you're doing and consider the risks.
September 1, 2006 Page 7  

 

 

Teilnahme an 34. jährlichen Konferenz der Sickle Cell Disease Association of America's (SCDAA)

http://biz.yahoo.com/bw/060912/20060912005290.html?.v=1

lg
o

 

nicht wirklich was.  

 

 

die Charttechnische Weiterentwicklung  

Ich sag es dir: erst hoch und dann runter, dann wieder hoch und wieder runter. Und so ungefähr 6 bis 12 Monate.

Die Xechem hat noch die dritte Entwicklungsphase vor sich. Die Produktion ist zwar eingeführt und angefangen, erwarte aber noch nicht, dass es schon morgen in der Kasse klingelt...

Der Chart:



 

die ist schnell für 40% gut  

gibt es news??? wer weiss was??  

jetzt schon 4 mio aktien  

 

 

 

zu haben  

0.0275 Up 0.0015 Up 5.77% 6,808,807